AR017523A1 - Compuestos de 4,5-diariloxazol procedimiento para prepararlos, las composiciones farmaceuticas formuladas con dichos compuestos y el procedimiento parapreparar dichas composiciones - Google Patents

Compuestos de 4,5-diariloxazol procedimiento para prepararlos, las composiciones farmaceuticas formuladas con dichos compuestos y el procedimiento parapreparar dichas composiciones

Info

Publication number
AR017523A1
AR017523A1 ARP980105363A ARP980105363A AR017523A1 AR 017523 A1 AR017523 A1 AR 017523A1 AR P980105363 A ARP980105363 A AR P980105363A AR P980105363 A ARP980105363 A AR P980105363A AR 017523 A1 AR017523 A1 AR 017523A1
Authority
AR
Argentina
Prior art keywords
compounds
procedure
hydrogen
single bond
prepare
Prior art date
Application number
ARP980105363A
Other languages
English (en)
Original Assignee
Fujisawa Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co filed Critical Fujisawa Pharmaceutical Co
Publication of AR017523A1 publication Critical patent/AR017523A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Se revelan compuestos de 4,5-diariloxazol caracterizados porque tienen la formula (I) donde R1 es hidrogeno o un grupo carboxiprotector, R2, R5, R6 y R7son hidrogeno o hidroxi, R3 y R4 cada uno son hidrogeno, o están combinados para formar un grupo epoxi o un enlace simple, R8 y R9 son grupos ariloopcionalmente sustituido, y X es un enlace simple o metileno, y además, R2 y R3 pueden estar combinados el uno con el otro para formar un enlace simple; ycuando R2, R5, R6 y R7 cada uno son hidrogeno,R3 y R4 forman un grupo expoxi; cuando R3 y R4 forman un enlace simple, al menos uno de R2, R5, R6 y R7 eshidroxi y el (los) otro(s) es (son) un hidrogeno y X es metileno, o sus sales, procedimiento para prepararlos, una composicion farmacéutica quelos incluye yel método para prepararla. Los compuestos (I) son agonistas de la prostaglandina I2 y por tanto son utiles para prevenir o tratar la obstruccion arterial,afecciones cerebrovasculares, cirrosis hepática, arterioesclerosis, isquemia cardíaca, isquemia cardíaca, hipertension dermatosis y enfermedades similares.
ARP980105363A 1997-10-27 1998-10-27 Compuestos de 4,5-diariloxazol procedimiento para prepararlos, las composiciones farmaceuticas formuladas con dichos compuestos y el procedimiento parapreparar dichas composiciones AR017523A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPP0032A AUPP003297A0 (en) 1997-10-27 1997-10-27 4,5-diaryloxazole compounds

Publications (1)

Publication Number Publication Date
AR017523A1 true AR017523A1 (es) 2001-09-12

Family

ID=3804308

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980105363A AR017523A1 (es) 1997-10-27 1998-10-27 Compuestos de 4,5-diariloxazol procedimiento para prepararlos, las composiciones farmaceuticas formuladas con dichos compuestos y el procedimiento parapreparar dichas composiciones

Country Status (12)

Country Link
US (1) US6297267B1 (es)
EP (1) EP1027340A1 (es)
JP (1) JP2001521029A (es)
KR (1) KR20010031204A (es)
CN (1) CN1278252A (es)
AR (1) AR017523A1 (es)
AU (1) AUPP003297A0 (es)
BR (1) BR9813281A (es)
CA (1) CA2307952A1 (es)
HU (1) HUP0004177A3 (es)
TW (1) TW450966B (es)
WO (1) WO1999021843A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP608898A0 (en) * 1998-09-23 1998-10-15 Fujisawa Pharmaceutical Co., Ltd. New use of prostaglandin E2 antagonists
US6437146B1 (en) 1998-09-25 2002-08-20 Fujisawa Pharmaceutical Co., Ltd. Oxazole compounds as prostaglandin e2 agonists or antagonists
AUPQ253199A0 (en) * 1999-08-30 1999-09-23 Fujisawa Pharmaceutical Co., Ltd. Non-prostanoid prostaglandin I2-agonist
TWI316055B (es) * 2001-04-26 2009-10-21 Nippon Shinyaku Co Ltd
MY163762A (en) * 2008-07-23 2017-10-31 Toray Industries Therapeutic agent for chronic renal failure

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5344836A (en) * 1991-11-11 1994-09-06 Ono Pharmaceutical Co., Ltd. Fused benzeneoxyacetic acid derivatives
US5362879A (en) * 1993-04-15 1994-11-08 Bristol-Myers Squibb Company 4-5-diphenyloxazole derivatives as inhibitors of blood platelet aggregation
ATE194335T1 (de) * 1993-12-20 2000-07-15 Fujisawa Pharmaceutical Co 4,5-diaryloxazol-derivate
HU224822B1 (en) 1994-03-10 2006-02-28 Fujisawa Pharmaceutical Co Naphthalene derivatives as prostaglandin i2 agonists, pharmaceutical compns. contg. them and process for preparing them
TW401408B (en) 1995-07-21 2000-08-11 Fujisawa Pharmaceutical Co Heterocyclic compounds having prostaglandin I2 agonism

Also Published As

Publication number Publication date
US6297267B1 (en) 2001-10-02
EP1027340A1 (en) 2000-08-16
TW450966B (en) 2001-08-21
CN1278252A (zh) 2000-12-27
HUP0004177A3 (en) 2002-10-28
BR9813281A (pt) 2000-08-22
JP2001521029A (ja) 2001-11-06
CA2307952A1 (en) 1999-05-06
WO1999021843A1 (en) 1999-05-06
HUP0004177A2 (hu) 2001-05-28
AUPP003297A0 (en) 1997-11-20
KR20010031204A (ko) 2001-04-16

Similar Documents

Publication Publication Date Title
AR041661A1 (es) Compuestos triciclicos utiles para el tratamiento de desordenes inflamatorios y alergicos procesos para su preparacion y composiciones farmaceuticas que lo contienen
BR9915895A (pt) Composto, uso do mesmo, processo para prepará-lo, método para o tratamento de um mamìfero, incluindo o homem, de condições resultantes de nìveis de circulação elevados de apob-100, e, composição farmacêutica
ES2181443T3 (es) Nuevos derivados de 3,3-difenilpropilaminas.
MX9300256A (es) Derivados de acido acetico y proceso para su preparacion.
AR050181A1 (es) Derivados de urea ciclicos sustituidos, su preparacion y su uso farmaceutico como inhibidores de quinasa
ES2067456T3 (es) Nuevos derivados de aminoacidos, procedimientos para su preparacion y composicion farmaceutica que los comprende.
ES2189330T3 (es) Derivados heterociclicos n6 de la adenosina sustituidos.
CO5580746A2 (es) Derivados de fenil-piperazina como inhibidores de la reabsorcion de la serotonina
BR0111230A (pt) Composto, e, uso e processo para a preparação do mesmo
PE20000048A1 (es) Prodrogas de inhibidores de aspartil proteasa
AR039124A1 (es) Derivados de adamantano, procedimiento de preparacion y composiciones farmaceuticas que los contienen
ES2059335T3 (es) Derivados de pirido(3,2,1-ij)-1,3,4-benzoxadiazina, procedimiento para su obtencion, preparados farmaceuticos correspondientes y productos intermedios utilizables en el procedimiento.
DK0521827T3 (da) Farmakologisk virksomme hydrazinderivater og fremgangsmåde til deres fremstilling
FI871981A (fi) Nya dopamin- -hydroxylas-inhibitorer.
AR017127A1 (es) Nuevos compuestos de piperazina y piperidina, un metodo para su preparacion, composiciones farmaceuticas que las contienen, metodos para prepararlas y nuevos compuestos intermedios para dicho metodo.
PE20001083A1 (es) Derivados de mononitrato de isosorbide
AR043537A1 (es) Derivados azabiciclicos de piridiloximetilo y bencisoxazol
AR118082A1 (es) Inhibidores de enzimas
AR017523A1 (es) Compuestos de 4,5-diariloxazol procedimiento para prepararlos, las composiciones farmaceuticas formuladas con dichos compuestos y el procedimiento parapreparar dichas composiciones
CO5640109A2 (es) Compuestos triciclicos inhibidores de la farnesisl proteino transferasa y composiciones farmaceuticas que los contienen
AR024222A1 (es) Imidazoles con actividad antiinflamatoria un procedimiento para su preparacion y composiciones farmaceuticas que lo contienen
AR018632A1 (es) Compuestos derivados de acido 1,2,3,4-tetrahidroquinolin-2-carboxilico, su uso en la fabricacion de medicamentos, composicion farmaceutica que los contiene, proceso para su preparacion.
ES2038654T3 (es) Un procedimiento para preparar derivados de tianafteno.
ES2057415T3 (es) Derivados biciclicos.
ES2174582T3 (es) Nuevos derivados de 1,2-ditiolano, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal